Journal
NATURE COMMUNICATIONS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-020-20602-5
Keywords
-
Categories
Funding
- Korea National Institute of Health fund [2020-ER5311-00, 2020-ER5323-00, 2019-NI-077-01, 2019-NG-044-01]
- Agency for Defense Development [011555-012664201]
- Ministry of Science and ICT [PRM1752011]
- Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program, Republic of Korea [KGM9942011, KGM4572013]
- Korea Health Promotion Institute [2019-NI-077-01, 2020-ER5311-00, 2020-ER5323-00, 2019-NG-044-01] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- Ministry of Science & ICT (MSIT), Republic of Korea [IBS-R008-D1-2021-A00] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- National Research Council of Science & Technology (NST), Republic of Korea [KGM4572013, KGM9942011] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
A human monoclonal antibody called CT-P59 has been shown to effectively neutralize SARS-CoV-2 and demonstrate significant therapeutic effects in animal models, making it a promising candidate for COVID-19 treatment.
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available